Test Price
2,800 AED✅ Home Collection Available
RYR1 Gene Central Core Disease & Malignant Hyperthermia NGS Genetic Test in UAE
Executive Summary & Core Metrics
Comprehensive NGS genetic analysis of the RYR1 gene for diagnosis of Central Core Disease and malignant hyperthermia susceptibility, with integrated clinical genetics consultation and ISO-certified home phlebotomy.
- Accuracy Guarantee: 99.9% diagnostic sensitivity using ISO 15189-accredited NGS with ACMG variant classification (AMP/CAP guidelines).
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM – 11 PM.
- Clinical Guidance: Post-test telephonic consultation by a DHA-licensed Consultant Medical Geneticist.
- Insurance & Billing: Direct billing verification via WhatsApp at +971 54 548 8731.
- Pricing: 2,800 AED (inclusive of genetic counseling and comprehensive report).
Test Overview & Methodology
This next-generation sequencing (NGS) test analyzes the complete coding region and flanking intronic boundaries of the RYR1 gene. It detects pathogenic and likely pathogenic variants associated with Central Core Disease (CCD) and susceptibility to malignant hyperthermia (MH). The test employs Illumina NovaSeq technology with greater than 500x average depth, enabling detection of single nucleotide variants, small insertions/deletions, and copy number variants. All variants are interpreted according to ACMG/AMP 2015 guidelines and reported with ClinVar and gnomAD population frequencies.
| Feature | DNA Labs UAE NGS Test | Closest Alternative |
|---|---|---|
| Precision | 100% coverage of all coding exons ± 20 bp flanking introns; average depth >500x; ACMG/AMP annotation | Targeted single-exon or hotspot analysis; misses deep intronic and regulatory variants |
| Method | Next Generation Sequencing (Illumina NovaSeq) with advanced bioinformatics pipeline | Sanger sequencing of limited regions; lower sensitivity for mosaic and multiexon deletions |
| Turnaround Time | 3 to 4 weeks from sample receipt | 4 to 6 weeks (frequently outsourced) |
| Clinical Utility | Comprehensive report including MH susceptibility guidance and anesthesia risk stratification | Limited to CCD genotype confirmation; no pharmacological correlation provided |
Physician Insight & Safety Protocols
“Identifying a pathogenic RYR1 variant is a critical step in preventing life-threatening malignant hyperthermia events during general anesthesia. However, careful correlation with personal and family history, as well as segregation analysis, is essential because not all detected variants are disease-causing. This test provides the molecular foundation for safe anesthetic planning and informed family counseling.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication and Anesthesia Precautions
Important: Do not discontinue or alter any prescribed muscle relaxants, anesthetics, or other medications without consulting your treating physician. If you have a known or suspected RYR1 variant, inform your anesthesiologist before any surgical procedure to ensure avoidance of triggering agents such as succinylcholine and volatile halogenated anesthetics.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide written informed consent; for minors, mandatory parental or guardian consent per UAE Federal Law.
- Exclusion: Recent blood transfusion or allogeneic bone marrow transplant (may compromise germline analysis).
- Red Flag: If you experience sudden severe muscle cramps, dark urine, or unexplained high fever following surgery, seek emergency medical attention immediately — these may signal malignant hyperthermia or rhabdomyolysis.
- Red Flag: Do not undergo general anesthesia with potential triggering agents until your RYR1 genetic test result has been reviewed by a qualified anesthesiologist.
Patient FAQ & Clinical Guidance
1. What is the RYR1 gene central core disease NGS test?
This advanced NGS test sequences the entire RYR1 gene to detect pathogenic variants associated with Central Core Disease and susceptibility to malignant hyperthermia. The result enables tailored medical management, informs anesthetic safety protocols, and helps families understand autosomal dominant inheritance patterns.
2. Why is this test important for anesthesia safety?
Identification of an RYR1 pathogenic variant allows avoidance of volatile anesthetics and succinylcholine, thereby preventing life-threatening malignant hyperthermia crises. A negative result does not completely eliminate risk, but a positive result mandates strict adherence to MH-safe anesthetic protocols in all future procedures.
3. How is the sample collected and what is the turnaround time?
A peripheral blood sample is collected by an ISO-certified phlebotomist at your home via VIP mobile phlebotomy service, available daily from 8 AM to 11 PM. Results are delivered within 3 to 4 weeks from sample receipt. Pre-test genetic counseling is provided to discuss implications, and a post-test teleconsultation clarifies your report.
UAE Regulatory & Data Privacy Adherence
This test and all associated data processing comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical laboratory operations adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds ISO 9001:2015 certification (Certificate: INT/EGQ/2509DA/3139) and is licensed by the Dubai Health Authority (DHA Facility License No. 1143). All genetic data is encrypted, access-controlled, and processed solely for diagnostic purposes with explicit patient consent.
Clinical & Logistical Metadata
| Test Name | RYR1 Gene Full Sequencing – Central Core Disease & Malignant Hyperthermia Susceptibility NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube) or FTA card spot; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | Next Generation Sequencing (Illumina NovaSeq) with ACMG/AMP variant interpretation; CNV detection by bioinformatics pipeline |
| ICD-10-CM Code | G71.21 (Central Core Disease), Z15.09 (Genetic susceptibility to malignant hyperthermia) |
| LOINC Code | 82319-9 (RYR1 gene full mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians